Mangrove Partners Aldeyra Therapeutics, Inc. Transaction History

Mangrove Partners

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$7.14 - $9.85 $5.05 Million - $6.97 Million	-707,746 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $1.86 Million - $3.92 Million	273,402 Added 62.95%	707,746 $9.77 Million
Q2 2018 Aug 14, 2018	BUY	$6.95 - $9.18 $766,758 - $1.01 Million	110,325 Added 34.05%	434,344 $3.45 Million
Q1 2018 May 15, 2018	BUY	$6.55 - $8.9 $1.05 Million - $1.42 Million	159,635 Added 97.11%	324,019 $2.43 Million
Q4 2017 Feb 14, 2018	BUY	$5.7 - $7.75 $936,988 - $1.27 Million	164,384	164,384 $1.12 Million

107

35.2M

153K

83.9K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $322M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Mangrove Partners, based on Form 13F filings with the SEC.

Stay updated on Mangrove Partners with notifications on news.